A-779 (trifluoro<wbr/>acetate salt)

A-779 (trifluoroacetate salt)

CAT N°: 23396
Price:

From 48.00 40.80

A-779 is a peptide antagonist of the Mas receptor, also known as the angiotensin (1-7) (Ang (1-7)) receptor (IC50 = 0.3 nM in a radioligand binding assay).{38671} It does not compete with angiotensin 1 (AT1) and AT2 receptor agonists for binding in adrenocortical membranes when used at a concentration of 1 µM and exhibits an IC50 value greater than 10 µM in adrenomedullary membranes.{38670} In vitro, A-779 inhibits Ang (1-7)-induced release of arachidonic acid from CHO cells transfected with Mas.{38671} A-779 (0.01 mg/kg) prevents the antidiuretic effects of Ang (1-7) in water-loaded rats. It also inhibits the Ang (1-7)-induced decrease in mean arterial pressure (MAP) when administered by microinjection into the nucleus of the solitary tract with no effect on basal MAP. A-779 increases urine flow rate and sodium excretion in male, but not female, rats when AT1 and AT2 receptors are blocked by the selective antagonists losartan (Item No. 10006594) and PD 123319 (Item No. 16099), respectively.{38669}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 5-L-isoleucine-7-D-alanine-1-7-angiotensin II, trifluoroacetate salt
  • Correlated keywords
    • 159432-28-7 A779 AT-1 2 Ang1 Ang2 Ang3 Ang4 Ang5 Ang6 Ang7 PD123319 anti-diuretic Ang1-7
  • Product Overview:
    A-779 is a peptide antagonist of the Mas receptor, also known as the angiotensin (1-7) (Ang (1-7)) receptor (IC50 = 0.3 nM in a radioligand binding assay).{38671} It does not compete with angiotensin 1 (AT1) and AT2 receptor agonists for binding in adrenocortical membranes when used at a concentration of 1 µM and exhibits an IC50 value greater than 10 µM in adrenomedullary membranes.{38670} In vitro, A-779 inhibits Ang (1-7)-induced release of arachidonic acid from CHO cells transfected with Mas.{38671} A-779 (0.01 mg/kg) prevents the antidiuretic effects of Ang (1-7) in water-loaded rats. It also inhibits the Ang (1-7)-induced decrease in mean arterial pressure (MAP) when administered by microinjection into the nucleus of the solitary tract with no effect on basal MAP. A-779 increases urine flow rate and sodium excretion in male, but not female, rats when AT1 and AT2 receptors are blocked by the selective antagonists losartan (Item No. 10006594) and PD 123319 (Item No. 16099), respectively.{38669}

We also advise you